Recent advances in prevention of hepatitis B recurrence after liver transplantation

World Journal of Gastroenterology

Volumn 21, Issue 3, 2015, Pages 829-835

  Xi, Zhi Feng ^a   Xia, Qiang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Entecavir; Hepatitis B immunoglobulin; Hepatitis B recurrence; Lamivudine; Liver transplantation; Tenofovir

Indexed keywords

ADEFOVIR; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS DNA; ANTIVIRUS AGENT; HEPATITIS B HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ANTIVIRAL RESISTANCE; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; END STAGE LIVER DISEASE; FLUSHING; FOLLOW UP; HEADACHE; HEPATITIS B; HUMAN; INFECTION PREVENTION; LIVER TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; NEPHROTOXICITY; RECURRENT INFECTION; REINFECTION; REVIEW; THORAX PAIN; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VIRUS LOAD; ADVERSE EFFECTS; ANIMAL; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; HEPATITIS B VIRUS; PATHOGENICITY; RECURRENT DISEASE; VIROLOGY; VIRUS ACTIVATION;

ANIMALS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; END STAGE LIVER DISEASE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; LIVER TRANSPLANTATION; RECURRENCE; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84921456688     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i3.829     Document Type: Review

References (62)

1. WHO. Hepatitis B fact sheet [cited 2014 Jun]. Available from: URL: http://www.who.int/mediacentre/factsheets/fs204/en/.
2. Pfitzmann R, Nüssler NC, Hippler-Benscheidt M, Neuhaus R, Neuhaus P. Long-term results after liver transplantation. Transpl Int 2008; 21: 234-246 [PMID: 18031464 DOI: 10.1111/j.1432-2277.2007.00596.x].
3. O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, Portmann B, Alexander GJ, Williams R. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992; 14: 104-111 [PMID: 1737910 DOI: 10.1016/0168-8278(92)90138-F].
4. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: 619-626 [PMID: 2010156 DOI: 10.1016/0270-9139(91)92554-L].
5. Lake JR, Wright TL. Liver transplantation for patients with hepatitis B: what have we learned from our results? Hepatology 1991; 13: 796-799 [PMID: 2010175].
6. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847 [PMID: 8247035 DOI: 10.1056/NEJM199312163292503].
7. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, Goss JA, Schmidt P, Pakrasi A, Artinian L, Murray NG, Imagawa DK, Holt C, Goldstein LI, Stribling R, Busuttil RW. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-589 [PMID: 9696028 DOI: 10.1002/hep.510280241].
8. Terrault NA, Wright TL. Hepatitis B virus infection and liver transplantation. Gut 1997; 40: 568-571 [PMID: 9203930 DOI: 10.1136/gut.40.5.568].
9. Fan XL, Zhang JS, Zhang XQ, Yue W, Ma L. Differential regulation of beta-arrestin 1 and beta-arrestin 2 gene expression in rat brain by morphine. Neuroscience 2003; 117: 383-389 [PMID: 12614678 DOI: 10.1034/j.1600-6143.2003.00063. x].
10. Katz LH, Paul M, Guy DG, Tur-Kaspa R. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis. Transpl Infect Dis 2010; 12: 292-308 [PMID: 20002355 DOI: 10.1111/j.1399-3062.2009.00470.x].
11. Riediger C, Berberat PO, Sauer P, Gotthardt D, Weiss KH, Mehrabi A, Merle U, Stremmel W, Encke J. Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation. 17890261 DOI: 10.1093/ndt/gfm655].
12. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6: 429-433 [PMID: 10915163].
13. Terrault NA, Vyas G. Hepatitis B immune globulin preparations and use in liver transplantation. Clin Liver Dis 2003; 7: 537-550 [PMID: 14509525 DOI: 10.1016/S1089-3261(03)00045-X].
14. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, Ascher NL, Wright TL. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24: 1327-1333 [PMID: 8938155].
15. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-1722 [PMID: 14724824 DOI: 10.1053/j.gastro.2003.09.033].
16. Cheng PN, Chang TT. Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients. Expert Rev Anti Infect Ther 2008; 6: 569-579 [PMID: 18847396 DOI: 10.1586/14787210.6.5.569].
17. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-1010 [PMID: 16525137 DOI: 10.1056/NEJMoa051285].
18. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-1020 [PMID: 16525138 DOI: 10.1056/NEJMoa051287].
19. Baldick CJ, Tenney DJ, Mazzucco CE, Eggers BJ, Rose RE, Pokornowski KA, Yu CF, Colonno RJ. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology 2008; 47: 1473-1482 [PMID: 18435459 DOI: 10.1002/hep.22211].
20. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006; 44: 1656-1665 [PMID: 17133475 DOI: 10.1002/hep.21422].
21. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514 [PMID: 19280622 DOI: 10.1002/hep.22841].
22. Wu B, Li T, Chen H, Shen J. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Value Health 2010; 13: 592-600 [PMID: 20561341 DOI: 10.1111/j.1524-4733.2010.00733.x].
23. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010].
24. Samuelson A, Morgan M, Reynolds J, Morgan M, Reynolds J, Lee M, Kamal A, Ahmed A. The Use of Entecavir Following Liver Transplantation: Pilot Safety and Tolerability Data. Amer J Gastroenterol 2008; 103 Suppl 1: S160.415 Abstract.
25. Xi ZF, Xia Q, Zhang JJ, Chen XS, Han LZ, Wang X, Shen CH, Luo Y, Xin TY, Wang SY, Qiu de K. The role of entecavir in preventing hepatitis B recurrence after liver transplantation. J Dig Dis 2009; 10: 321-327 [PMID: 19906113 DOI: 10.1111/j.1751-2980.2009.00403.x].
26. Kim YK, Kim SH, Lee SD, Park SJ. Clinical outcomes and risk factors of hepatitis B virus recurrence in patients who received prophylaxis with entecavir and hepatitis B immunoglobulin following liver transplantation. Transplant Proc 2013; 45: 3052-3056 [PMID: 24157034 DOI: 10.1016/j.tran sproceed.2013.08.065].
27. Cai CJ, Lu MQ, Chen YH, Zhao H, Li MR, Chen GH. Clinical study on prevention of HBV re-infection by entecavir after liver transplantation. Clin Transplant 2012; 26: 208-215 [PMID: 21981656 DOI: 10.1111/j.1399-0012.2011.01448.x].
28. Ueda Y, Marusawa H, Kaido T, Ogura Y, Ogawa K, Yoshizawa A, Hata K, Fujimoto Y, Nishijima N, Chiba T, Uemoto S. Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after living-donor liver transplantation. Hepatol Res 2013; 43: 67-71 [PMID: 22548744 DOI: 10.1111/j.1872-034X.2012.01020.x].
29. Hu TH, Chen CL, Lin CC, Wang CC, Chiu KW, Yong CC, Liu YW, Eng HL. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation. Transplantation 2014; 97 Suppl 8: S53-S59 [PMID: 24849836 DOI: 10.1097/01.tp.0000446278.43804.f9].
30. Perrillo R, Buti M, Durand F, Charlton M, Gadano A, Cantisani G, Loong CC, Brown K, Hu W, Lopez-Talavera JC, Llamoso C. Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver Transpl 2013; 19: 887-895 [PMID: 23788462 DOI: 10.1002/lt.23690].
31. Na GH, Kim DG, Han JH, Kim EY, Lee SH, Hong TH, You YK, Choi JY. Prevention and risk factors of hepatitis B recurrence after living donor liver transplantation. J Gastroenterol Hepatol 2014; 29: 151-156 [PMID: 24117684 DOI: 10.1111/jgh.12403].
32. De Clercq, E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003; 16: 569-596 [PMID: 14557287 DOI: 10.1128/CMR.16.4.569-596.2003].
33. Gallant JE, Deresinski S. Tenofovir disoproxil fumarate. Clin Infect Dis 2003; 37: 944-950 [PMID: 13130407 DOI: 10.1086/378068].
34. Jones J, Colquitt J, Shepherd J, Harris P, Cooper K. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection. Health Technol Assess 2010; 14 Suppl 1: 23-29 [PMID: 20507800 DOI: 10.3310/hta14Suppl1/04].
35. Lee CI, Kwon SY, Kim JH, Choe WH, Lee CH, Yoon EL, Yeon JE, Byun KS, Kim YS, Kim JH. Efficacy and safety of tenofovirbased rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure. Gut Liver 2014; 8: 64-69 [PMID: 24516703 DOI: 10.5009/gnl.2014.8.1.64].
36. Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, Kitrinos K, Svarovskaia ES, Miller MD, Sorbel J, Heathcote J, Marcellin P, Borroto-Esoda K. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011; 53: 763-773 [PMID: 21374657 DOI: 10.1002/hep.24078].
37. Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Dinh P, Martins EB, Yee LJ, Flaherty JF, Kitrinos KM, Rustgi VK, Marcellin P. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology 2013; 58: 505-513 [PMID: 23364953 DOI: 10.1002/hep.26277].
38. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132-143 [PMID: 20955704 DOI: 10.1053/j.gastro.2010.10.011].
39. Jiménez-Pérez M, Sáez-Gómez AB, Mongil Poce L, Lozano-Rey JM, de la Cruz-Lombardo J, Rodrigo-López JM. Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant. Transplant Proc 2010; 42: 3167-3168 [PMID: 20970638 DOI: 10.1016/j.transproceed.2010.05.127].
40. Teperman LW, Poordad F, Bzowej N, Martin P, Pungpapong S, Schiano T, Flaherty J, Dinh P, Rossi S, Subramanian GM, Spivey J. Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transpl 2013; 19: 594-601 [PMID: 23447407 DOI: 10.1002/lt.23628].
41. Fox AN, Terrault NA. The option of HBIG-free prophylaxis against recurrent HBV. J Hepatol 2012; 56: 1189-1197 [PMID: 22274310 DOI: 10.1016/j.jhep.2011.08.026].
42. Naoumov NV, Lopes AR, Burra P, Caccamo L, Iemmolo RM, de Man RA, Bassendine M, O'Grady JG, Portmann BC, Anschuetz G, Barrett CA, Williams R, Atkins M. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001; 34: 888-894 [PMID: 11451173 DOI: 10.1016/S0168-8278(01)00039-3].
43. Buti M, Mas A, Prieto M, Casafont F, González A, Miras M, Herrero JI, Jardí R, Cruz de Castro E, García-Rey C. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003; 38: 811-817 [PMID: 12763375 DOI: 10.1016/S0168-8278(03)00087-4].
44. Park SJ, Paik SW, Choi MS, Lee JH, Koh KC, Kim SJ, Joh JW, Lee SK. Is lamivudine with 1-week HBlg as effective as long-term high-dose HBlg in HBV prophylaxis after liver transplantation? Transplant Proc 2002; 34: 1252-1254 [PMID: 12072331 DOI: 10.1016/S0041-1345(02)02637-4].
45. Buti M, Mas A, Prieto M, Casafont F, González A, Miras M, Herrero JI, Jardi R, Esteban R. Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation 2007; 84: 650-654 [PMID: 17876280 DOI: 10.1097/01.tp.0000277289.23677.0a].
46. Tanaka T, Benmousa A, Marquez M, Therapondos G, Renner EL, Lilly LB. The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantation. Clin Transplant 2012; 26: E561-E569 [PMID: 23061767 DOI: 10.1111/ctr.12022].
47. Neff GW, Kemmer N, Kaiser TE, Zacharias VC, Alonzo M, Thomas M, Buell J. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin. Dig Dis Sci 2007; 52: 2497-2500 [PMID: 17404847 DOI: 10.1007/s10620-006-9658-3].
48. Gane EJ, Strasser S, Patterson S, McCaughan GW, Angus PW. A prospective study on the safety and efficacy of lamivudine and adefovir dipivoxil prophylaxis in HBsAg positive liver transplantation candidates. Hepatology 2007; 46 suppl 1: abstracts 479A.
49. Gane EJ, Patterson S, Strasser SI, McCaughan GW, Angus PW. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl 2013; 19: 268-274 [PMID: 23447403 DOI: 10.1002/lt.23600].
50. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008; 48: 1460-1466 [PMID: 18925641 DOI: 10.1002/hep.22524].
51. Cholongitas E, Vasiliadis T, Antoniadis N, Goulis I, Papanikolaou V, Akriviadis E. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation. Transpl Infect Dis 2012; 14: 479-487 [PMID: 22624695 DOI: 10.1111/j.1399-3062.2012.00741.x].
52. Nath DS, Kalis A, Nelson S, Payne WD, Lake JR, Humar A. Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transplant 2006; 20: 206-210 [PMID: 16640528].
53. Cholongitas E, Goulis I, Antoniadis N, Fouzas I, Imvrios G, Papanikolaou V, Akriviadis E. New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence. Transpl Int 2014; 27: 1022-1028 [PMID: 24909714 DOI: 10.1111/tri.12370].
54. Yi NJ, Choi JY, Suh KS, Cho JY, Baik M, Hong G, Lee KW, Kim W, Kim YJ, Yoon JH, Lee HS, Kim DG. Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin. J Gastroenterol 2013; 48: 1401-1410 [PMID: 23463400 DOI: 10.1007/s00535-013- 0761-x].
55. Tanaka T, Renner EL, Selzner N, Therapondos G, Lilly LB. One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation. Can J Gastroenterol Hepatol 2014; 28: 41-44 [PMID: 24212911].
56. Wesdorp DJ, Knoester M, Braat AE, Coenraad MJ, Vossen AC, Claas EC, van Hoek B. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective. J Clin Virol 2013; 58: 67-73 [PMID: 23880162].
57. Stravitz RT, Shiffman ML, Kimmel M, Puri P, Luketic VA, Sterling RK, Sanyal AJ, Cotterell AH, Posner MP, Fisher RA. Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation. Liver Int 2012; 32: 1138-1145 [PMID: 22348467 DOI: 10.1111/j.1478-3231.2012.02770.x].
58. Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, Dai WC, Chan AC, Cheung TT, Tsang S, Lam B, Lai CL, Lo CM. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011; 141: 1212-1219 [PMID: 21762659 DOI: 10.1053/j.gastro.2011.06.083].
59. Wadhawan M, Gupta S, Goyal N, Taneja S, Kumar A. Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis. Liver Transpl 2013; 19: 1030-1035 [PMID: 23788470 DOI: 10.1002/lt.23692].
60. Marzano A, Gaia S, Ghisetti V, Carenzi S, Premoli A, Debernardi- Venon W, Alessandria C, Franchello A, Salizzoni M, Rizzetto M. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005; 11: 402-409 [PMID: 15776431 DOI: 10.1002/lt.20402].
61. Wu LM, Xu X, Zheng SS. Hepatitis B virus reinfection after liver transplantation: related risk factors and perspective. Hepatobiliary Pancreat Dis Int 2005; 4: 502-508 [PMID: 16286252].
62. Kasraianfard A, Watt KD, Lindberg L, Alexopoulos S, Rezaei N. HBIG Remains Significant in the Era of New Potent Nucleoside Analogues for Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. Int Rev Immunol 2014; Epub ahead of print [PMID: 24911598 DOI: 10.3109/08830185.2014.921160].